- Home
- ENVB vs ATCH Comparison
ENVB vs ATCH Comparison
Compare ENVB & ATCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVB
- ATCH
- Stock Information
- Founded
- ENVB 1994
- ATCH 2022
- Country
- ENVB United States
- ATCH United States
- Employees
- ENVB N/A
- ATCH N/A
- Industry
- ENVB Biotechnology: Pharmaceutical Preparations
- ATCH
- Sector
- ENVB Health Care
- ATCH
- Exchange
- ENVB Nasdaq
- ATCH Nasdaq
- Market Cap
- ENVB 3.2M
- ATCH 3.4M
- IPO Year
- ENVB N/A
- ATCH N/A
- Fundamental
- Price
- ENVB $1.28
- ATCH $0.30
- Analyst Decision
- ENVB Strong Buy
- ATCH
- Analyst Count
- ENVB 1
- ATCH 0
- Target Price
- ENVB $10.00
- ATCH N/A
- AVG Volume (30 Days)
- ENVB 42.6K
- ATCH 1.1M
- Earning Date
- ENVB 05-19-2025
- ATCH 05-27-2025
- Dividend Yield
- ENVB N/A
- ATCH N/A
- EPS Growth
- ENVB N/A
- ATCH N/A
- EPS
- ENVB N/A
- ATCH 2.67
- Revenue
- ENVB N/A
- ATCH N/A
- Revenue This Year
- ENVB N/A
- ATCH N/A
- Revenue Next Year
- ENVB N/A
- ATCH N/A
- P/E Ratio
- ENVB N/A
- ATCH $0.13
- Revenue Growth
- ENVB N/A
- ATCH N/A
- 52 Week Low
- ENVB $1.01
- ATCH $0.28
- 52 Week High
- ENVB $222.75
- ATCH $84.00
- Technical
- Relative Strength Index (RSI)
- ENVB 31.74
- ATCH 28.46
- Support Level
- ENVB $1.23
- ATCH $0.28
- Resistance Level
- ENVB $1.40
- ATCH $0.35
- Average True Range (ATR)
- ENVB 0.09
- ATCH 0.04
- MACD
- ENVB 0.15
- ATCH 0.04
- Stochastic Oscillator
- ENVB 48.15
- ATCH 11.29
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
About ATCH AtlasClear Holdings Inc. Common Stock
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.